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ABSTRACT
In atherosclerotic animal models, the cyclo-oxygenase (COX)-inhibitor aspirin 
counteracts downregulation of endothelial-derived netrin-1, thus reducing arterial 
inflammation. We here explored the effect of aspirin on netrin-1 in healthy subjects 
undergoing influenza immunisation, which is an established experimental model of 
inflammation-related endothelial dysfunction.
Our data showed that netrin-1 undergoes reduction (-29.25% from baseline; 
p=0.0017) in the presence of endothelial activation (VCAM-1 rose by 9.98% 2-days 
post-vaccination; p=0.0022). Aspirin counteracted vaccine-induced endothelial 
activation and reduction of netrin-1 in a dose-dependent manner (-3.06% and 
-17.03% from baseline at a dose of 300mg and 75mg respectively; p=0.0465 and 
p>0.05 vs untreated). Clopidogrel, which was used as a comparator due to its 
similar anti-platelet activity, also reduced endothelial activation but, unlike aspirin, 
enhanced netrin-1 levels (+20.96% from baseline; p=0.0033 vs untreated). A 
correlation analysis incorporating cytokines, hs-CRP, VCAM-1, TXB2 and PGE2, showed 
that changes in netrin-1 were directly related to PGE2 variations only (r=0.6103; 
p=0.0002). In a separate population of 40 healthy unimmunised volunteers, 28-day 
treatment with aspirin 300mg reduced netrin-1 (-18.76% from baseline; p=0.0012) 
without affecting endothelial markers or hs-CRP; as expected, aspirin suppressed 
TXB2 and PGE2. Netrin-1 and PGE2 levels were directly related (r=0.358; p=0.0015), 
but other parameters including TXB2, hs-CRP and endothelial markers, were not.
In conclusion, aspirin counteracts downregulation of netrin-1 following 
endothelial dysfunction due to its anti-inflammatory effect on the activated 
endothelium. However, inhibition of COX-dependent prostanoids negatively modulates 
netrin-1 synthesis in healthy subjects, and this could give rise to aspirin-dependent 
reduction in netrin-1 under steady state conditions.
INTRODUCTION
Netrins are a class of laminin-like proteins, 
which were initially isolated within the central nervous 
system and identified as regulators of embryonic axonal 
guidance. Netrin-1, by far the best-characterised member 
of the group, has subsequently been found to have a wide 
spectrum of regulatory roles in numerous pathological 
conditions, given its broad expression in inflammatory, 
vascular and tumour cell types and ability to control their 
survival, apoptosis and migration. Netrin-1 has become 
particularly relevant within the field of oncology, where 
it has been shown to be of both diagnostic and prognostic 
value in many cancer subtypes [1, 2], and there is much 
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interest in the development of therapeutic antibodies that 
interfere with netrin-1-dependent pathways as a potentially 
novel chemotherapeutic approach [3]. Netrin-1 is also 
emerging as a therapeutic target in cardiovascular disease 
[4], having been shown in pre-clinical studies to modulate 
atherogenesis via the control of arterial inflammation [5], 
as well as exerting cardio- and renoprotective actions [6, 
7]; and in this context, enhancing netrin-1 signalling may 
be desirable.
To date, there has been limited characterisation of 
the in vivo pathways that regulate netrin-1 expression 
in humans, which may compromise the development 
of targeted therapeutic strategies to achieve either a 
stimulatory or an inhibitory effect on the synthesis of this 
important molecule in various clinical settings. Moreover, 
different isoforms of netrin-1 are produced which are 
differently regulated. Our previous work on the vascular 
endothelium [8] has showed that NF-κB activation, 
as induced by pro-inflammatory stimuli, up-regulates 
the synthesis of the nuclear isoform of netrin-1, which 
is involved in cell survival [9, 10]. On the contrary, a 
reduction in the secretion of the endothelial-derived full-
length isoform of netrin-1, which protects against arterial 
inflammation, occurs in response to pro-inflammatory/
proatherogenic stimuli as a consequence of endothelial 
damage. Administration of aspirin counteracted 
the downregulation of netrin-1 within the vascular 
endothelium in a murine model of atherosclerosis, leading 
to a beneficial action in terms of the inflammatory plaque 
component [8].
In the current study, we investigated the effect 
of endothelial dysfunction on the circulating levels of 
netrin-1 in humans. Endothelial dysfunction is a systemic 
perturbation of vascular homeostasis characterised 
by impaired endothelium-dependent vasodilation and 
an associated state of endothelial activation, which 
is not only triggered by pathological stimuli in the 
context of cardiovascular diseases but also occurs as 
part of physiological host defence mechanisms during 
inflammation [11, 12]. In keeping with this, vaccine 
administration is regarded as a valid human experimental 
model to study cardiovascular physiology, since the 
mild systemic inflammation triggered by immunisation 
induces a transient endothelial dysfunction [13, 14]. In this 
context, the therapeutic potential of the cyclo-oxygenase 
(COX) inhibitor, aspirin, in modulating netrin-1 synthesis 
was studied.
RESULTS
Endothelial dysfunction results in reduced 
circulating levels of netrin-1
Immunisation has previously been reported to 
induce vascular dysfunction in healthy volunteers [11, 
15]. In accordance with these data, the present study 
demonstrated an increase in serum level of VCAM-1, 
which rose from a baseline level of 493.7 ± 44.34 ng/ml 
to 542.3 ± 49.60 ng/ml post-influenza immunisation, in 
participants untreated with anti-platelet agents (Group 4; 
p=0.0022 vs baseline). In the same subjects, circulating 
levels of netrin-1 underwent a reduction of approximately 
30%, from 311.9 (IQR 248.0 – 316.3) pg/ml at baseline 
to 220.2 (IQR 202.2 – 287.7) pg/ml post-immunisation 
(p=0.0017; Figure 1).
All anti-platelet drug regimes tested suppressed 
this rise in VCAM-1, although the 300 mg dose of 
aspirin appeared to be more effective at doing so than 
both the 75 mg dose of aspirin and clopidogrel (Figure 
1). Aspirin counteracted the suppression of netrin-1 post-
immunisation in a dose-dependent manner (% change 
from baseline in Groups 1 and 2 were -3.06 and -17.03 
respectively; p=0.0465 and p>0.05 vs untreated), whilst a 
significant increase in the level of netrin-1 was observed 
in the clopidogrel group (20.96% change from baseline; 
p=0.0033 vs untreated) (Figure 1).
Levels of serum TXB
2
, a marker of platelet 
activation, which is widely used as an indicator of 
aspirin responsiveness, fell significantly, from 3416.0 ± 
285.7 ng/ml at baseline to 3130.0 ± 244.0 ng/ml post-
immunisation, in the group receiving aspirin 300 mg for 
28 days (p=0.0296). There was a reduction in TXB
2
 also in 
those participants on aspirin 75 mg for 48 hours, however 
this did not reach statistical significance (p=0.2103). 
Post-immunisation TXB
2
 levels remained stable in the 
untreated participants, reflecting a lack of pro-thrombotic 
effect of influenza immunisation; also, clopidogrel did 
not influence serum TXB
2
 levels, in agreement with prior 
findings showing no effect of clopidogrel on TXB
2
 when 
administered to healthy volunteers in the absence of pro-
thrombotic stimuli [16] (Figure 1). On the contrary, levels 
of PGE
2
, which is known to have a protective effect on 
the vascular endothelium under steady state conditions 
[17–20] and whose concentration is regulated by a balance 
between its COX-dependent synthesis and degradation 
rates [21], fell from 320.9± 55.04 pg/ml to 189.5 ±30.37 
pg/ml in the untreated participants (p=0.0199 vs baseline). 
PGE
2
 reduction post-immunisation was attenuated by 
aspirin treatment, whilst in the clopidogrel-treated group, 
a non-significant trend towards an increase in PGE
2
 was 
observed (Figure 1). Overall, post-immunisation changes 
in PGE
2
 and netrin-1 followed the same pattern in the 
different groups (Figure 1).
Netrin-1 levels are directly associated with PGE2 
production
In a multiple regression analysis of the correlation 
between netrin-1 levels and all other study parameters, 
including markers of endothelial function, TXB
2
 and 
PGE
2
, as well as previously measured and reported 
parameters (hs-CRP, cytokines, P-selectin levels and 
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monocyte cell subset count), we found that changes in 
netrin-1 levels in response to immunisation either with 
or without anti-platelet treatment were linearly and 
directly related with changes in PGE
2
 concentration only 
(r=0.6103; p=0.0002; Figure 1).
Previous experimental data have demonstrated 
that netrin-1 inhibits PGE
2
 production via suppression 
of COX-2 expression. However, in contrast, our data 
showed a direct and positive relationship between these 
two parameters. In order to further delineate their mutual 
interaction, we measured netrin-1 levels in the cohort of 
healthy subjects taking 28 days of treatment with 300 mg 
aspirin, which primarily targets the synthesis of COX-
dependent eicosanoids. Drug treatment in this cohort, 
as expected, led to a significant reduction in both TXB
2
 
and PGE
2
 levels (Figure 2). This latter fell from 331.9 
± 69.04 pg/ml at baseline to 89.99 ± 34.29 pg/ml post-
aspirin therapy (p=0.0114). Serum VCAM-1 remained 
unchanged from baseline levels of 527.32 ± 15.46 ng/
ml to 519.10±15.76 ng/ml post-treatment. ICAM-1 and 
E-selectin were also unchanged, indicating no effect of 
aspirin on the inflammatory status of the endothelium in 
these study participants. Levels of hs-CRP were also not 
affected (Figure 2).
Interestingly, there was a mild but consistent 
reduction in serum netrin-1, from a baseline level of 303.9 
(IQR: 218.4 – 386.0) pg/ml to 246.9 (IQR: 193.2 – 316.2) 
pg/ml post-aspirin therapy (p=0.0012) (Figure 2). When 
combining baseline and post-treatment values of all study 
variables, a strong positive correlation was found between 
netrin-1 and PGE
2
 levels (r=0.3584; p=0.0015) only. The 
percentage change in netrin-1 was found to be negatively 
Figure 1: Influenza immunisation induced a rise in the endothelial marker VCAM-1 (Panel A), with a concomitant reduction in serum 
prostaglandin E2 (PGE2; Panel B) and netrin-1 (Panel D). All anti-platelet drug regimes abolished these effects. Serum thromboxane 
B
2
 (TXB
2
) was reduced in those taking aspirin 300 mg (Panel C). There was a positive correlation between change in netrin-1 and PGE
2
 
(Panel E). High-sensitivity C-reactive protein (hs-CRP; Panel F) was elevated in all participants, whilst there was no significant reduction 
in pro-inflammatory cytokines, interleukin 1 beta (IL-1β; Panel G), interleukin-6 (IL-6; Panel H), and tumour necrosis factor alpha 
(TNF-α; Panel I). Values are reported as either mean with SEM or median and IQR. P values are shown where data are significant.
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correlated with serum salicylate levels (r=-0.5370; 
p=0.0100), indicating that the reduction in netrin-1 was a 
consequence of aspirin therapy (Figure 2).
To characterise the netrin-1 isoform that was being 
measured in serum samples by ELISA, we performed 
Western blotting using a rat anti-netrin-1 antibody to 
specifically target the full length (70 kDa) protein and a 
goat anti-netrin-1 antibody against the truncated (55 kDa) 
protein. We were only able to detect the truncated isoform 
of netrin-1 in serum samples (Figure 2).
DISCUSSION
Our prior work both in vitro and in a mouse 
model of atherosclerosis (8) have demonstrated that a 
dysfunctional endothelium markedly loses its ability to 
secrete netrin-1, and this compromises the integrity of the 
vascular barrier against inflammatory cell infiltration. The 
current clinical study confirms these experimental data, 
whilst offering insight into the biomolecular mechanisms 
that regulate the synthesis of vascular netrin-1 in humans 
under physiological conditions.
Endothelial activation in response to influenza 
immunisation was confirmed by the increased level 
of VCAM-1 observed in our subjects 48 hours post-
immunisation, supporting the validity of influenza 
immunisation as an experimental model to study the 
relationship between endothelial dysfunction and 
circulating levels of netrin-1 in humans. In accordance 
with prior studies performed in several animal models 
of inflammation [8, 22, 23], we found that endothelial 
activation, as driven by mild inflammation, is paralleled 
by a reduction in the serum concentration of netrin-1 in 
healthy subjects. This effect was abolished by anti-platelet 
treatment independently of their mode of action or of their 
ability to suppress systemic inflammation. Indeed, we have 
Figure 2: In healthy volunteers, aspirin 300 mg administered for 28 days led to a reduction in serum prostaglandin E2 (PGE2; Panel B) 
and netrin-1 (Panel C), as well as thromboxane B2 (TXB2; Panel A). The reduction in netrin-1 was associated with increased serum 
salicylate levels (Panel E), while there was a positive correlation between netrin-1 and PGE
2
 levels (Panel F). There was no change in 
markers of endothelial dysfunction, vascular cell adhesion molecule-1 (VCAM-1; Panel G), intracellular adhesion molecule (ICAM-1; 
Panel H), or E-selectin (Panel I). High-sensitivity C-reactive protein (hs-CRP) levels remained unchanged post treatment (Panel J). 
Western blotting was performed to identify both the full length, 70 kDa netrin-1 protein and the truncated, 55 kDa netrin-1 protein, but only 
the truncated isoform was detected (Panel D).
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previously reported the lack of efficacy of both aspirin 
and clopidogrel in modulating the rise in hs-CRP with 
this experimental model of inflammation [24]. Moreover, 
whilst aspirin 300 mg exerted the strongest inhibition on 
platelet activity, as evidenced by greater suppression of 
P-selectin (10) and TXB
2
 in response to immunisation than 
with clopidogrel, this latter was better at restoring netrin-1 
levels post-immunisation. All anti-platelet agents exerted 
comparable effects in terms of suppression of the rise in 
VCAM-1 induced by immunisation. However, aspirin, 
which specifically inhibits COX activity, suppressed PGE
2
 
levels and the degree of suppression of PGE
2
 was directly 
related to changes in netrin-1 levels in both studies.
Our data demonstrate that netrin-1 reduction, as 
occurs in the presence of a dysfunctional endothelium 
caused by immunisation, occurs in parallel with PGE
2
 
reduction. On the other hand, pharmacological inhibition 
of PGE
2
 as induced by the COX-inhibitor aspirin, also 
produced a small but significant decrease in netrin-1 
levels, in the absence of endothelial dysfunction. The 
TXA
2
-pathway does not appear to be involved in netrin-1 
regulation, inasmuch as modulation of netrin-1, both in 
subjects receiving influenza immunisation and in those 
receiving high-dose aspirin for 28 days, was not related 
to changes in serum TXB
2
. Although we measured PGE
2
 
here, we cannot exclude the possibility that additional 
COX-dependent endothelium-derived prostanoids, such 
as prostacyclin, that generally follow the same pattern 
of expression in healthy endothelium [25], may show a 
similar association with netrin-1 under these experimental 
conditions. However, considering the prior demonstrated 
modulatory effect of netrin-1 on COX-2 expression and 
PGE
2
 synthesis, it is intriguing to note the existence of 
a regulatory link between COX-activity, COX-dependent 
prostaglandin production, and netrin-1 that may have 
important functional and therapeutic implications.
Numerous studies have demonstrated that PGE
2
 
is protective against endotoxin injury, and promotes 
endothelial barrier enhancement [17–20, 26, 27] as well 
as cell survival [28, 29]. The observed reduction in PGE
2
 
in response to immunisation was abolished by all anti-
platelet therapy regimes, likely due to their beneficial 
effect on the vascular endothelium that, in turn, preserved 
its ability to synthesise protective vasoactive molecules 
and/or reduced PGE
2
 consumption. Of note, there was 
a tendency towards an increase in PGE
2
 levels in those 
taking clopidogrel, which we attribute to the suppression 
of endothelial activation driven by clopidogrel, without 
the additional effect of COX-inhibition leading to reduced 
PGE
2
 production which occurs with aspirin therapy. The 
anti-inflammatory action exerted by anti-platelet agents on 
the vasculature that was seen in this study could partly 
be ascribed to their ability to suppress expansion of the 
pro-inflammatory monocytes that we have previously 
demonstrated in this human model of inflammation [24]. 
However, a few differences were noted in this clinical 
study compared to our previous pre-clinical work using the 
same anti-platelet agents [8]. The superior effect of aspirin 
over clopidogrel in counteracting netrin-1 reduction in 
atherosclerotic mice was not observed in this clinical 
study; rather, clopidogrel demonstrated a better ability to 
maintain circulating levels of netrin-1 in the presence of 
Table 1: Baseline characteristics of study population
Gender
(n)
Age
(years)
SBP
(mmHg)
DBP
(mmHg)
BMI  
(kg/m2)
HDL chol 
(mmol/l)
LDL chol 
(mmol/l)
Triglycerides 
(mmol/l) hsCRP (mg/l)
Group 1: 
aspirin 300
n =9
3 male
6 female
32.00
(30.00 - 37.00)
119 ± 6 82 ± 3
23.114
(20.91 - 26.50)
1.83
(1.32 – 2.34)
2.74
(2.39 - 3.50)
1.09
(0.81 - 1.59)
0.45
(0.1 – 0.90)
Group 2: 
aspirin 75
n = 9
4 male
5 female
33.00
(29.99 - 41.00)
123 ± 6 82 ± 4
25.26
(22.18 - 28.13)
1.77
(1.30 – 1.99)
2.73
(2.22 - 3.38)
0.99
(0.69 - 1.57)
0.50
(0.40 – 1.00)
Group 3: 
clopidogrel
n = 9
3 male
6 female
33.50
(32.00 - 43.75)
125 ± 4 84 ± 3
25.00
(20.43 - 28.67)
1.71
(1.45 – 2.12)
2.49
(2.26 - 3.14)
0.93
(0.77 - 1.53)
0.60
(0.20 – 0.93)
Group 4: 
untreated
n = 9
4 male
5 female
37.00
(32.00 - 42.00)
124 ± 4 83 ± 2
24.11
(21.73 - 28.69)
1.66
(1.28 – 2.08)
2.52
(2.06- 3.32)
1.06
(0.73 – 1.64)
0.45
(0.28 – 0.65)
Unvaccinated 
group
n = 40
16 male
24 female
32.75
(30.25 - 39.75)
122 ± 5 82 ± 4
22.80
(20.78 – 26.14)
1.88
(1.52 – 2.01)
2.41
(2.17 – 3.01)
1.01
(0.78 – 1.33)
0.77
(0.34 – 1.60)
Biometric data and cardiovascular risk profiles for the subjects in all groups are shown. Values are expressed as the mean ± SEM or median (IQR). SBP: 
systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; HDL: high density lipoprotein; LDL: low density lipoprotein; hsCRP: 
high-sensitivity C-reactive protein.
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endothelial dysfunction in humans. This discrepancy may 
be attributable to the distinct modulation of the tested anti-
platelet agents on PGE
2
 production, which has emerged 
as an important factor implicated in the regulation of 
netrin-1 in human physiological settings. Moreover, we 
were only able to detect the truncated isoform of netrin-1 
in the blood of our subjects, whilst our previous in vitro 
experiments on endothelial cells reported a specific action 
of aspirin exerted on the full-length secreted isoform of the 
protein through an epigenetic modification of chromatin. 
Whether lack of expression of full-length netrin-1 is due to 
the phenomenon of protein truncation occurring in human 
serum cannot be excluded. Of note, in revising our prior 
published in vitro tests performed on human endothelial 
cells, we noted that stimulation with aspirin alone (in 
the absence of TNF as a co-stimulatory agent) showed 
a tendency, albeit not statistically significant, towards a 
reduction in netrin-1 release in serum supernatants by 
vascular cells compared to untreated ones. In light of 
the new data that has emerged from the current clinical 
study, it is likely that the aspirin-induced PGE
2
 reduction, 
which we reported in the aforementioned in vitro set of 
experiments, have accounted for a subtle difference in 
netrin-1 that only became evident and statistically relevant 
in the in vivo human studies here described.
In conclusion, our data suggest that circulating 
netrin-1 levels are directly modulated by changes in the 
status of activation of the vascular endothelium as well 
by changes in COX-dependent vasoactive prostanoids, 
such as PGE
2
, in healthy subjects. Given the emerging 
role of netrin-1 in cardiovascular disease and as an 
oncological target, further delineation of the pathways that 
control netrin-1 production under both physiological and 
pathological conditions, may allow development of useful 
and novel therapies based on netrin-1 modulation.
MATERIALS AND METHODS
Participant recruitment
This was a post-hoc investigation conducted on 
a total of 76 healthy volunteer subjects, previously 
recruited at Guy’s and St Thomas’ Hospitals, London, 
who underwent two separate clinical studies and for whom 
serum samples were still available. All participants were 
aged 18 years or older (median: 31 years; IQR 25 - 38), 
had no significant medical history, were not taking regular 
medications, and had not taken anti-platelet or anti-
inflammatory drugs in addition to the study medications 
described below.
36 of these subjects were participants in a study 
previously reported by our group [24], in which influenza 
immunisation was used as an experimental model of 
mild inflammation to evaluate the effect of different anti-
platelet therapy regimes on a number of inflammatory 
biomarkers, including cytokines, monocyte phenotype, 
and high-sensitivity C-reactive protein (hs-CRP). Serum 
samples were collected before and 48 hours after receiving 
the seasonal influenza vaccine [24], and in the presence 
of one of the following treatments: aspirin 300 mg once 
daily (Group 1; n = 9); aspirin 75 mg once daily (group 
2; n = 9); or clopidogrel with an initial loading dose of 
300 mg followed by a further dose of 75 mg 24 h later 
(Group 3; n = 9) - see Table 1. Immunised participants 
on no anti-platelet treatment (Group 4, n=9) served as 
controls. For the purpose of the current study, stored serum 
samples were used to measure netrin-1, vascular cell 
adhesion molecule-1 (VCAM-1, as a marker of endothelial 
activation), prostaglandin E
2
 (PGE
2
, which has been 
demonstrated to exert vascular protective effects [18, 27] 
and is known to be regulated by netrin-1 via suppression 
of COX-2 [30], and thromboxane B
2
 (TXB
2
), as indicators 
of response to COX-inhibition [16]. Data were pooled 
with previously collected information, including hs-CRP, 
P-selectin and cytokine levels and monocyte phenotype as 
previously published [16].
The other 40 subjects were previously recruited into 
a clinical study designed to identify novel biomarkers 
of aspirin resistance in response to 28 days of treatment 
with aspirin 300 mg once daily [31]. The same markers 
as above were measured in stored serum samples, with 
the exception of TXB
2
, which had been previously 
assessed in urine samples. In addition to VCAM-1, further 
endothelial markers, including E-selectin and intercellular 
adhesion molecule-1 (ICAM-1) were also assessed in 
this population. hs-CRP was also measured in stored 
samples (Quintiles Drug Research Unit, London). Among 
previously measured parameters for this population, 
salicylate levels were available in a subpopulation of 22 
individuals.
The clinical studies were reviewed and given 
favourable opinion by the NRES London—Dulwich 
Research Ethics Committee (ref. number 13/LO/1664; 
South London network study identification number 16644) 
and the Riverside Research Ethics Committee, London, 
UK (ref. number 07/Q0401/1) and registered on the UK 
Clinical Research Network Portfolio. All participants gave 
informed consent. The studies were performed conforming 
to the Declaration of Helsinki.
Enzyme-linked immunosorbent assays
Enzyme-linked immunosorbent assays (ELISAs) 
were carried out to measure serum levels of netrin-1 
(SEB827Hu, Cloud-Clone Corp., China), PGE
2
 
(MBS007171, MyBioSource, Inc., USA), TXB
2
 (CSB-
E08046h, Cusabio, China), VCAM-1 (DVC00, R&D 
Systems, UK), ICAM-1 (850.540.096, Diaclone, France) 
and E-selectin (CSB-E04540h, Cusabio, China). All 
kits were commercially available and used as per the 
manufacturer instructions. Inter-assay variability of all kits 
was found to be <5%.
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Western blot
Western blotting of serum samples was performed 
with both rat anti-netrin-1 and goat anti-netrin-1 primary 
antibodies as previously described by our group. Prior 
to use, serum was treated, as per previously reported 
methodology [32], for lipid, IgG and albumin depletion. 
Briefly, samples were centrifuged for 15 minutes at 
15000 x g at room temperature to remove the lipid 
component; IgG depletion was subsequently performed 
on the delipidated serum with a Protein G Sepharose bead 
suspension (10278424, GE Healthcare Ltd, UK), and was 
followed by centrifugation in cold ethanol to remove the 
albumin-rich serum fraction [32].
Proteins were subsequently re-suspended in 
radioimmunoprecipitation assay (RIPA) buffer and measured 
by BCA assay. 10 μg of each protein sample was separated 
on a SDS-PAGE gel (10% acrylamide), and transferred 
to a polyvinylidene difluoride membrane. After 1 hour 
blocking in phosphate buffer saline containing 5% milk / 
0.1% Tween-20, the membranes were probed with either 
rat anti-netrin-1 or goat anti-netrin-1 antibodies (both 1:100 
in blocking solution; R&D System), for 2 hours at room 
temperature. After washing, membranes were incubated 
with goat anti-rat or donkey anti-goat secondary antibodies 
as appropriate (1:2000; Cell Signalling, UK). Bands were 
detected with enhanced chemiluminescence reagent on 
Hyperfilm (Amersham Biosciences, UK).
Statistics
Statistical analyses were performed using GraphPad 
Prism (version 6.0) software. Parametric data are 
expressed as the mean ± standard error of mean (SEM), 
whilst non-parametric data are expressed as the median 
with interquartile ranges (IQR). ANOVA was used to 
compare percentage variation of each study variable 
between the 4 immunisation groups in the vaccine study. 
Baseline and post-treatment values were compared within 
each group using a paired parametric or non-parametric 
test as appropriate. Netrin-1 correlation with the other 
study variables was analysed by Spearman correlation test 
(since netrin-1 was not normally distributed). A p value of 
<0.05 was taken as statistically significant.
Abbreviations
COX: cyclo-oxygenase; CRP: C-reactive protein; 
hsCRP: high sensitivity C-reactive protein; ICAM-1: 
intracellular adhesion molecule; PGE2: prostaglandin E2; 
TXB2: thromboxane B2; VCAM-1: vascular cell adhesion 
molecule-1.
Author contributions
Drs Kerry Layne, Timothy Goodman and Gabriella 
Passacquale conducted the laboratory work. Drs Kerry 
Layne and Gabriella Passacquale performed the statistical 
analyse. All authors contributed to the manuscript and 
approved its finalised contents. Gabriella Passacquale 
supervised the work.
ACKNOWLEDGMENTS
We wish to thank the GSTT occupational health and 
pharmacy departments for their assistance, as well as the 
GSTT staff who participated in this study.
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
FUNDING
This work was supported by a grant from the British 
Heart Foundation (ref. FS/13/45/30345).
REFERENCES
1. Ramesh G, Berg A, Jayakumar C. Plasma netrin-1 is a 
diagnostic biomarker of human cancers. Biomarkers. 
2011;16:172-80.
2. Yildirim ME, Kefeli U, Aydin D, Sener N, Gumus M. The 
value of plasma netrin-1 in non-small cell lung cancer 
patients as diagnostic and prognostic biomarker. Tumour 
Biol. 2016;37:11903-7.
3. Grandin M, Meier M, Delcros JG, Nikodemus D, Reuten R, 
Patel TR, Goldschneider D, Orriss G, Krahn N, Boussouar 
A, Abes R, Dean Y, Neves D, et al. Structural decoding 
of the netrin-1/UNC5 interaction and its therapeutical 
implications in cancers. Cancer Cell. 2016;29:173-85.
4. Layne K, Ferro A, Passacquale G. Netrin-1 as a novel 
therapeutic target in cardiovascular disease: to activate or 
inhibit? Cardiovasc Res. 2015;107:410-9.
5. van Gils JM, Derby MC, Fernandes LR, Ramkhelawon 
B, Ray TD, Rayner KJ, Parathath S, Distel E, Feig JL, 
Alvarez-Leite JI, Rayner AJ, McDonald TO, O'Brien KD, 
et al. The neuroimmune guidance cue netrin-1 promotes 
atherosclerosis by inhibiting the emigration of macrophages 
from plaques. Nat Immunol. 2012;13:136-43.
6. Bouhidel JO, Wang P, Li Q, Cai H. Pharmacological 
postconditioning treatment of myocardial infarction with 
netrin-1. Front Biosci (Landmark Ed). 2014;19:566-70.
7. Zhang J, Cai H. Netrin-1 prevents ischemia/reperfusion-
induced myocardial infarction via a DCC/ERK1/2/eNOS 
s1177/NO/DCC feed-forward mechanism. J Mol Cell 
Cardiol. 2010;48:1060-70.
8. Passacquale G, Phinikaridou A, Warboys C, Cooper 
M, Lavin B, Alfieri A, Andia ME, Botnar RM, Ferro A. 
Aspirin-induced histone acetylation in endothelial cells 
enhances synthesis of the secreted isoform of netrin-1 thus 
inhibiting monocyte vascular infiltration. Br J Pharmacol. 
2015;172:3548-64.
Oncotarget86555www.impactjournals.com/oncotarget
9. Delloye-Bourgeois C, Goldschneider D, Paradisi A, 
Therizols G, Belin S, Hacot S, Rosa-Calatrava M, Scoazec 
JY, Diaz JJ, Bernet A, Mehlen P. Nucleolar localization of 
a netrin-1 isoform enhances tumor cell proliferation. Sci 
Signal. 2012;5:ra57.
10. Paradisi A, Maisse C, Bernet A, Coissieux MM, Maccarrone 
M, Scoazec JY, Mehlen P. NF-kappaB regulates netrin-1 
expression and affects the conditional tumor suppressive 
activity of the netrin-1 receptors. Gastroenterology. 
2008;135:1248-57.
11. Hingorani AD, Cross J, Kharbanda RK, Mullen MJ, 
Bhagat K, Taylor M, Donald AE, Palacios M, Griffin GE, 
Deanfield JE, MacAllister RJ, Vallance P. Acute systemic 
inflammation impairs endothelium-dependent dilatation in 
humans. Circulation. 2000;102:994-9.
12. Donald AE, Charakida M, Cole TJ, Friberg P, Chowienczyk 
PJ, Millasseau SC, Deanfield JE, Halcox JP. Non-invasive 
assessment of endothelial function: which technique? J Am 
Coll Cardiol. 2006;48:1846-50.
13. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function 
and dysfunction: testing and clinical relevance. Circulation. 
2007;115:1285-95.
14. Hadi HA, Carr CS, Al Suwaidi J. Endothelial dysfunction: 
cardiovascular risk factors, therapy, and outcome. Vasc 
Health Risk Manag. 2005;1:183-98.
15. Vlachopoulos C, Xaplanteris P, Sambatakou H, Mariolis 
E, Bratsas A, Christoforatou E, Miliou A, Aznaouridis K, 
Stefanadis C. Acute systemic inflammation induced by 
influenza A (H1N1) vaccination causes a deterioration in 
endothelial function in HIV-infected patients. HIV Med. 
2011;12:594-601.
16. Fontana P, Nolli S, Reber G, de Moerloose P. Biological 
effects of aspirin and clopidogrel in a randomized cross-
over study in 96 healthy volunteers. J Thromb Haemost. 
2006;4:813-9.
17. Di Francesco L, Totani L, Dovizio M, Piccoli A, Di 
Francesco A, Salvatore T, Pandolfi A, Evangelista V, 
Dercho RA, Seta F, Patrignani P. Induction of prostacyclin 
by steady laminar shear stress suppresses tumor necrosis 
factor-alpha biosynthesis via heme oxygenase-1 in human 
endothelial cells. Circ Res. 2009;104:506-13.
18. Birukova AA, Zagranichnaya T, Fu P, Alekseeva E, Chen 
W, Jacobson JR, Birukov KG. Prostaglandins PGE(2) and 
PGI(2) promote endothelial barrier enhancement via PKA- 
and Epac1/Rap1-dependent Rac activation. Exp Cell Res. 
2007;313:2504-20.
19. Razandi M, Pedram A, Rubin T, Levin ER. PGE2 and 
PGI2 inhibit ET-1 secretion from endothelial cells by 
stimulating particulate guanylate cyclase. Am J Physiol. 
1996;270:H1342-9.
20. Eskildsen MP, Hansen PB, Stubbe J, Toft A, Walter S, 
Marcussen N, Rasmussen LM, Vanhoutte PM, Jensen 
BL. Prostaglandin I2 and prostaglandin E2 modulate 
human intrarenal artery contractility through prostaglandin 
E2-EP4, prostacyclin-IP, and thromboxane A2-TP receptors. 
Hypertension. 2014;64:551-6.
21. Kalinski P. Regulation of immune responses by 
prostaglandin E2. J Immunol. 2012;188:21-8.
22. van Gils JM, Ramkhelawon B, Fernandes L, Stewart 
MC, Guo L, Seibert T,  Menezes GB, Cara DC, Chow 
C, Kinane TB, Fisher EA, Balcells M, Alvarez-Leite J, 
et al. Endothelial expression of guidance cues in vessel 
wall homeostasis dysregulation under proatherosclerotic 
conditions. Arterioscler Thromb Vasc Biol. 2013;33:911-9.
23. Ly NP, Komatsuzaki K, Fraser IP, Tseng AA, Prodhan 
P, Moore KJ, Kinane TB. Netrin-1 inhibits leukocyte 
migration in vitro and in vivo. Proc Natl Acad Sci U S A. 
2005;102:14729-34.
24. Layne K, Di Giosia P, Ferro A, Passacquale G. Anti-
platelet drugs attenuate the expansion of circulating 
CD14highCD16+ monocytes under pro-inflammatory 
conditions. Cardiovasc Res. 2016;111:26-33.
25. Smyth EM, Grosser T, Wang M, Yu Y, FitzGerald 
GA. Prostanoids in health and disease. J Lipid Res. 
2009;50:S423-8.
26. Conary JT, Parker RE, Christman BW, Faulks RD, King 
GA, Meyrick BO, Brigham KL. Protection of rabbit 
lungs from endotoxin injury by in vivo hyperexpression 
of the prostaglandin G/H synthase gene. J Clin Invest. 
1994;93:1834-40.
27. Bouchard JF, Chouinard J, Lamontagne D. Participation 
of prostaglandin E2 in the endothelial protective effect of 
ischaemic preconditioning in isolated rat heart. Cardiovasc 
Res. 2000;45:418-27.
28. Chen M, Divangahi M, Gan H, Shin DS, Hong S, Lee DM, 
Serhan CN, Behar SM, Remold HG. Lipid mediators in 
innate immunity against tuberculosis: opposing roles of 
PGE2 and LXA4 in the induction of macrophage death. J 
Exp Med. 2008;205:2791-801.
29. Lima J, Siqueira M, Pedro T, Ponte C, Peres L, Marinho 
S, Castello-Branco LR, Antas PR. The role of host soluble 
inflammatory mediators induced by the BCG vaccine for 
the initiation of in vitro monocyte apoptosis in healthy 
Brazilian volunteers. J Inflamm (Lond). 2015;12:60.
30. Ranganathan PV, Jayakumar C, Mohamed R, Dong Z, 
Ramesh G. Netrin-1 regulates the inflammatory response 
of neutrophils and macrophages, and suppresses ischemic 
acute kidney injury by inhibiting COX-2-mediated PGE2 
production. Kidney Int. 2013;83:1087-98.
31. Floyd CN, Goodman T, Becker S, Chen N, Mustafa A, 
Schofield E, Campbell J, Ward M, Sharma P, Ferro A. 
Increased platelet expression of glycoprotein IIIa following 
aspirin treatment in aspirin-resistant but not aspirin-
sensitive subjects. Br J Clin Pharmacol. 2014;78:320-8.
32. Fu Q, Bovenkamp DE, Van Eyk JE. A rapid, economical, 
and reproducible method for human serum delipidation and 
albumin and IgG removal for proteomic analysis. Methods 
Mol Biol. 2007;357:365-71.
